Stock Track | Fosun Pharma Soars After China Approves New Anti-Anxiety Drug

Stock Track10-18

Shares of Fosun Pharma (HKG:2196, SHA:600196) soared over 5% on Thursday, after the company's subsidiary received approval from China's medical regulator for a new anti-anxiety drug. The approval could provide a significant boost to Fosun Pharma's product portfolio and future revenue prospects.

The drug, venlafaxine hydrochloride sustained-release tablets, has been approved for the treatment of depression, including depression with anxiety, and general anxiety disorder. This approval marks an important milestone for the company as it looks to expand its presence in the lucrative Chinese pharmaceutical market.

Fosun Pharma is a leading pharmaceutical company in China, with a diverse range of products spanning various therapeutic areas. The company has a strong focus on research and development, and has been actively seeking regulatory approvals for new drugs to drive long-term growth.

The approval of the new anti-anxiety drug is particularly significant given the growing prevalence of mental health issues in China. As the country's population ages and stress levels increase, demand for effective treatments for conditions like anxiety and depression is expected to rise substantially. Fosun Pharma's new offering could position the company to capture a significant share of this growing market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188546047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-18 14:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188546047","market":"us","top_or_hot":-1,"title":"Stock Track | Fosun Pharma Soars After China Approves New Anti-Anxiety Drug","media":"Stock Track","content":"<p>Shares of Fosun Pharma (HKG:2196, SHA:600196) soared over 5% on Thursday, after the company's subsidiary received approval from China's medical regulator for a new anti-anxiety drug. The approval could provide a significant boost to Fosun Pharma's product portfolio and future revenue prospects.</p>\n\n<p>The drug, venlafaxine hydrochloride sustained-release tablets, has been approved for the treatment of depression, including depression with anxiety, and general anxiety disorder. This approval marks an important milestone for the company as it looks to expand its presence in the lucrative Chinese pharmaceutical market.</p>\n\n<p>Fosun Pharma is a leading pharmaceutical company in China, with a diverse range of products spanning various therapeutic areas. The company has a strong focus on research and development, and has been actively seeking regulatory approvals for new drugs to drive long-term growth.</p>\n\n<p>The approval of the new anti-anxiety drug is particularly significant given the growing prevalence of mental health issues in China. As the country's population ages and stress levels increase, demand for effective treatments for conditions like anxiety and depression is expected to rise substantially. Fosun Pharma's new offering could position the company to capture a significant share of this growing market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Fosun Pharma Soars After China Approves New Anti-Anxiety Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Fosun Pharma Soars After China Approves New Anti-Anxiety Drug\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-18 14:23 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Fosun Pharma (HKG:2196, SHA:600196) soared over 5% on Thursday, after the company's subsidiary received approval from China's medical regulator for a new anti-anxiety drug. The approval ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1188546047","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188546047","pubTimestamp":1729232602,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Fosun Pharma  soared over 5% on Thursday, after the company's subsidiary received approval from China's medical regulator for a new anti-anxiety drug. The approval could provide a significant boost to Fosun Pharma's product portfolio and future revenue prospects.The drug, venlafaxine hydrochloride sustained-release tablets, has been approved for the treatment of depression, including depression with anxiety, and general anxiety disorder. This approval marks an important milestone for t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"中国批准抗焦虑新药后复星医药飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shares of Fosun Pharma (HKG:2196, SHA:600196) soared over 5% on Thursday, after the company's subsidiary received approval from China's medical regulator for a new anti-anxiety drug. The approval could provide a significant boost to Fosun Pharma's product portfolio and future revenue prospects.\nThe drug, venlafaxine hydrochloride sustained-release tablets, has been approved for the treatment of depression, including depression with anxiety, and general anxiety disorder. This approval marks an important milestone for the company as it looks to expand its presence in the lucrative Chinese pharmaceutical market.\nFosun Pharma is a leading pharmaceutical company in China, with a diverse range of products spanning various therapeutic areas. The company has a strong focus on research and development, and has been actively seeking regulatory approvals for new drugs to drive long-term growth.\nThe approval of the new anti-anxiety drug is particularly significant given the growing prevalence of mental health issues in China. As the country's population ages and stress levels increase, demand for effective treatments for conditions like anxiety and depression is expected to rise substantially. Fosun Pharma's new offering could position the company to capture a significant share of this growing market.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188546047"}